The development of therapies aimed to promote remyelination is a major issue in chronic inflammatory demyelinating disorders of the central nervous system (CNS) such as multiple sclerosis (MS), where the permanent neurological impairment is due to the axonal loss resulting from recurrent episodes of immune-mediated demyelination. Here, we show that the intrathecal injection of a herpes simplex virus (HSV) type-1 replication-defective multigene vector, engineered with the human fibroblast growth factor (FGF)-II gene
Introduction
The pathological hallmark of multiple sclerosis (MS) is the presence within the central nervous system (CNS) of inflammatory infiltrates containing few autoreactive T cells and a multitude of pathogenic nonspecific lymphocytes determining patchy demyelination, axonal loss and severe glial scarring. 1, 2 It is currently believed that CNS antigen-specific T cells provide the organ specificity of the pathogenic process and regulate the influx within the CNS of non-antigen-specific mononuclear cells that, in turn, act as effector cells by directly destroying oligodendrocytes and/or by releasing myelinotoxic substances. 3 In most instances, however, oligodendrocytes or their precursors are morphologically preserved in demyelinating plaques, and remain capable of differentiating and remyelinating. 2, 4 A successful therapeutic approach of MS should therefore be aimed to inhibit the activation of antigen-and non-antigen-specific immune cells and/or to rescue the surviving oligodendrocytes within demyelinating plaques. CNS gene delivery using non-replicative viral vectors able to infect post-mitotic cells such as those resident in the CNS, is becoming a useful therapeutic approach to deliver anti-inflammatory cytokine genes able to inhibit the activation of antigen-and non-antigenspecific immune cells 5 and possibly, growth factor genes able to rescue surviving oligodendrocytes within demyelinating plaques.
We have recently developed a novel system to deliver cytokine genes into the CNS, based on the use of herpex simplex virus (HSV) type 1-derived non-replicative vectors injected into the cerebrospinal fluid (CSF) space. 6 HSV-1-derived vectors are easily transferred within the CNS through the CSF route, diffuse consistently in all ventricular and subarachnoid spaces, are able to efficiently infect the layer of ependymal and leptomeningeal cells surrounding the CSF space. Vectors redirect the cell machinery of the infected cells to produce discrete levels of the cytokine in the CSF for at least 4 weeks. We used vectors containing the prototypic anti-inflammatory cytokine IL-4 as a gene therapy model in experimental autoimmune encephalomyelitis (EAE) both in mice and non-human primates. 7, 8 In both animal models we found that the CNS delivery of the IL-4 gene was effective in ameliorating immunopathological signs of the disease. This therapeutic approach has the following major advantages: (1) availability of high cytokine levels in all areas of the CNS (MS is a multifocal disease); (2) persistent therapeutic effect for over 4 weeks after a single vector administration (irrespective of the injection site into the CSF circulation); (3) absence of CNS or peripheral side/toxic effects; and (4) lack of CNS-confined or peripheral immune-reactivity against the vector.
The development of therapies aimed to promote remyelination is a major issue in MS, where repeated episodes of demyelination over time lead to axonal loss and permanent neurological impairment. 2, 4 Therapies aimed to promote myelin restoration are so far mainly based on transplantation of oligodendrocytes (or oligodendrocyte precursors) or multipotential neural stem cells, 9 and on the use of neurotrophic growth factors able to promote migration, proliferation and differentiation of oligodendrocyte precursors. 10 Transplantation experiments have been successful in repairing the myelin sheath and restoring axonal conduction only in defined demyelinating areas of experimental animals, 11 thus being unuseful, at present, in multifocal CNS demyelinating diseases. Growth factor therapy has been partially successful in EAE, [12] [13] [14] but not in MS patients where it was hampered by heavy side-effects. 15, 16 However, results in humans are still preliminary and questionable (ie natural inactive TGF␤1 was used in EAE while active TGF␤1 was used in MS patients).
Here, we apply in EAE mice the gene therapy protocol we have established for IL-4, but using an HSV-1-replication-defective multigene vector engineered with the human fibroblast growth factor (FGF)-II gene (TH:bFGF). 17, 18 FGF-II is a neurotrophic growth factor able to promote migration and proliferation of oligodendrocyte precursor cells. 19 The intrathecal delivery into C57BL/6 mice with ongoing EAE of the TH:bFGF vector determined in situ short-term production of FGF-II leading to amelioration of clinical and pathological signs of EAE via a significant increase of the recruitment of oligodendrocyte precursors into CNS areas of demyelination.
Results

FGF-II is produced within the CNS after i.c. delivery of the TH:bFGF vector
CNS distribution of the TH:bFGF vector and the in situ production of the transgene (ie FGF-II) was studied in 16 'naive' C57BL/6 mice which were killed 2 days, 1 week and 2 weeks after vector injection into the cisterna magna (i.c.). FGF-II-stained cells were found in the CNS of C57BL/6 'naive' mice killed 2 days (Figure 1a (Figure 1h ). FGF-II was measured in CSF samples, from 'naive' TH:bFGF-injected mice, obtained from 2 days to 2 weeks after vector injection (range: 342.8-1636 pg/ml).
These data indicate that intrathecal delivery of the TH:bFGF vector determined a selective infection of CNSresident cells facing the CSF space leading to a sustained production and secretion of FGF-II into the CSF circulation lasting, at least, 2 weeks after vector injection.
CNS delivery of the TH:bFGF vector ameliorates ongoing EAE
After preliminary positive results on a small number of non-randomized mice, chronic EAE was induced in 12 C57BL/6 mice which were i.c. injected with the TH:bFGF or the THZ vector after disease onset. Before treatment, mice with established EAE were randomized into two groups according to disease onset and clinical score. Six mice (mean EAE onset: 14.5 ± 3.6 days post-immunization (p.i.), mean EAE score at vector injection: 1.9 ± 0.8) received one i.c. injection of the TH:bFGF vector at day 20 p.i.. and six mice (mean EAE onset: 14.8 ± 1.7 days p.i., mean EAE score at vector injection: 1.7 ± 0.3) received the THZ control vector using the same administration protocol. TH:bFGF-treated mice showed a significant (P Ͻ 0.05) recovery from the disease starting at day 25 p.i. and continuing thereafter until the completion of the study (Figure 2a Clinical data indicate that FGF-II production within the CNS, induced by i.c. injection of the FGF-II-containing vector, rapidly ameliorated the clinical signs of EAE. The disease-ameliorating effect due to the vector was longlasting.
EAE recovery in FGF-II-treated mice is associated with the increase of the number of oligodendrocyte precursors and myelin-forming cells in demyelinating areas
Neuropathological studies were performed in all EAE mice at the time of death (60 days p.i.). Results are summarized in Table 1 Table 1 ). In the very same areas, a significant (P р 0.0005) increase of proteolipid protein (PLP)-expressing oligodendrocytes was also measured in TH:bFGF-treated mice (Figure 5g and h) compared with control mice (Figure 5c and d) ( Table 1) .
week (c, d) and 2 weeks (e, f) after vector injection. Ependymal cells (continuous arrows) and choroidal cells (dashed arrows) area stained in all three mice for FGF-II (a, c, e: ×20) and HSV-1 (b, d, f: ×63). (g, h) Periventricular area from a representative control mouse i.c. injected with the THZ control vector and killed 1 week later. Ependymal cells (continuous arrows) and choroidal cells (dashed arrows) are not stained in the control mouse for FGF-II (g, ×20), but are positive for HSV-1 (h, ×20). Microscopic CNS examination did not show any toxic effects related to the injection procedure or to the vectors (ie inflammatory infiltrates).
Figure 2 EAE clinical course in C57BL/6 mice immunized with MOG 35-55 peptide and i.c. injected with the TH:bFGF vector (-᭺-) or with the THZ control vector (-᭹-). (a) Mean daily EAE score (±s.e.) in the two groups of mice (y-axis) during the post-immunization (p.i.) follow-up period (x-axis
Neuropathological findings indicate that the sustained disease-ameliorating effect observed after the treatment with the TH:bFGF vector was associated with a significant decrease of the extent of CNS demyelination and axonal loss. These pathological findings were paralleled by the reduction of effector cells and by the increase of myelin-forming cells within demyelinating areas.
Discussion
The failure of myelin repair in inflammatory demyelinating diseases, such as MS, is thought to be due to the depletion of oligodendrocyte precursors rather than to the destruction of terminally differentiated oligodendrocytes which are per se unable to repeat a program of axon ensheatment. 20, 21 Here, we report that CNS injection of an HSV-1-derived vector, able to induce in situ production of FGF-II, significantly ameliorates clinical and pathological signs of established EAE. Clinical recovery was associated with a significant increase of oligodendrocyte precursors and of PLP-expressing myelin-forming oligodendrocytes into areas of demyelination and axonal loss.
We previously showed that the intrathecal (ie CNS) injection of non-replicative HSV-1 vectors containing cytokine genes determined a unique and non-toxic infection of CNS-resident cells facing the CSF space (ie ependymal, choroidal and leptomeningeal cells). [6] [7] [8] Infected cells efficiently transcribed and translated the (trans)genes contained in the vectors (ie cytokines) for up to 3-4 weeks, and secreted the cytokines into the CSF circulation. Cytokines, in turn, reached the CNS parenchyma via the trans-ependymal/pial route although their diffusion from the CSF compartment to the CNS parenchyma was restricted to a few millimeters in subpial and subependymal areas. 6 We show here that i.c. injection of an FGF-II gene-containing HSV-1 vector induces CNS production and secretion of FGF-II into the CSF space from vector-infected cells located around the CSF space. 
u. of the THZ control vector (a-c) or with the TH:bFGF vector (d-f). Both mice have been killed 40 days after vector injection. (a, d) Inflammatory infiltrates in the posterior column of the spinal cord which are predominant in the control mouse (a, H&E staining, ×20) compared with the TH:bFGFtreated mouse (d, H&E, ×20). (b, c, e, f) The same spinal cord areas as in (a) and (d) but stained for macrophages (b and e, ×63) and CD3 + cells (c and f, ×63). Fewer macrophages (arrows) and T cells (arrows) are detectable in the TH:bFGF-treated mouse compared with the control mouse.
FGF-II secretion protects mice from clinicopathological signs of EAE by inducing a significant increase of the number of oligodendrocyte precursors and of myelinforming oligodendrocytes in areas of demyelination and axonal loss.
How can we explain the disease-ameliorating effect observed in FGF-II-treated mice? Recent evidence indicates that oligodendrocyte precursor cells (1) are the major source of 'remyelinating cells'; 21 (2) are present in rodent adult nervous system; 22 (3) can survive within demyelinating lesions; 23 and (4) can only be recruited into areas of demyelination over distances no greater than 1-2 mm. 24 Thus, we attribute the disease-ameliorating effect to the FGF-II-mediated recruitment into demyelinating areas of oligodendrocyte precursors located in close vicinity to or surviving within demyelinating lesions which, in turn, differentiated into myelin-forming cells.
The close contiguity (ie dorsal column of the spinal cord) of demyelinating areas to the subpial space, where FGF-II is produced, makes this scenario realistic. Although we do not have direct evidence of remyelination, the parallel increase of oligodendrocyte precursors and PLP-expressing oligodendrocytes, in the very same CNS areas, allow us to speculate that CNS-produced FGF-II might have induced the surviving oligodendrocyte precursors to migrate, proliferate and, subsequently, differentiate into myelin-forming cells. Our results are also supported by the fact that PLP-expressing oligodendrocytes are considered myelin-forming cells derived from oligodendrocyte precursors. 25 Our results also show a rapid amelioration of EAE after the FGF-II treatment. Although we cannot exclude that this finding may be due to the FGF-II-mediated increase of migration speed of oligodendrocyte precursor cells 
u. of the THZ control vector (a, b) or with the TH:bFGF vector (c, d). Both mice have been killed 40 days after vector injection. (a, c) Demyelination (Kluver-Barrera, ×20) in the posterior column (arrows). (b, d) Axonal loss (Bielshowsky, ×20) in the same spinal cord area as in (a) and (c).
Figure 5 Myelin-forming cells in the spinal cord of two representative C57BL/6 mice affected by EAE and treated, after EAE onset, with one i.c. injection of 10 7 p.f.u. of the THZ control vector (a-d) or with the TH:bFGF vector (e-h). The posterior column of the spinal cords of the two mice is stained for PDGFR␣ (a and e, ×20; b and f, ×40). PDGFR␣-positive cells (ie oligodendrocyte progenitors) are more abundant (arrows) in the demyelinating areas of TH:bFGF treated mice than in those of THZ-treated control mice. Adjacent tissue sections from the same spinal cord areas have been stained by in situ hybridization for PLP (c and g, ×20; d and h, ×63). Stained cells are PLP-expressing (myelin-forming) oligodendrocytes and are more abundant in TH:bFGF-treated mice than in controls (arrows).
into demyelinating areas, 26 it is tempting to speculate that FGF-II in itself might have an anti-inflammatory effect. This latter hypothesis is supported by the significant decrease of T cells and macrophages that we found in the CNS of FGF-II-treated mice compared with controls, and from recent findings indicating that CD44-mediated migration of leukocyte into the extravascular compartment, 27 which is a crucial event in autoimmunity, can be limited by binding of FGF-II to the CD44 receptor. 28 
Gene Therapy
Recent in vitro studies showed that FGF-II blocks terminal differentiation of oligodendrocyte precursors into mature cells thus impairing myelinating processes. 19 Our results, along with preliminary observations indicating that repeated injection of the TH:bFGF vector partially abrogated the beneficial effect observed after a single vector injection (RF, personal comunication), support the concept that CNS short-term production of FGF-II by triple-mutant HSV-1 vectors may partially circumvent this therapy-threatening side-effect. The short-term CNS production of FGF-II (in the early phase of EAE) might have induced the migration and proliferation of oligodendrocyte precursors into demyelinated areas, and the 'physiologic' shut-off of the vector after 2-3 weeks, might have allowed 'remyelination' through the differentiation of the recruited progenitors into myelin-forming cells.
In conclusion, our study further supports the role of growth factors as potential 'remyelinating' agents in demyelinating diseases and indicates that pulse CNS (gene) therapy with neurotrophic growth factors may represent a valuable alternative to promote the recruitment of myelin-forming cells into demyelinating areas and to avoid CNS-confined or peripheral side-effects due to chronic and/or systemic administration.
Materials and methods
HSV-1-derived vectors
Two different vectors were used. The first one (TH:bFGF vector) contained the rat FGF-II gene (95% homology with the mouse FGF-II gene and complete cross-species reactivity) driven by the human cytomegalovirus (HCMV) immediate-early promoter. 17 The second construct (thereafter referred to as the control vector) contained the Escherichia coli LacZ gene, driven by the HCMV immediate-early promoter (THZ vector). All expression cassettes were inserted into the thymidine kinase (tk) locus on a triple-deleted recombinant HSV-1 vector lacking three different immediate-early genes (ICP4, ICP27, ICP22) and showing low cytotoxicity and a high level of transgene expression.
17,18
Intrathecal HSV-1-vector injection HSV-1-derived vectors were injected into the cisterna magna (i.c.) of 6-to 8-week-old C57BL/6 female mice (Charles River, Calco, Italy) as previously described. 13, 14 Each mouse received one i.c. injection of 10 l (1 × 10 7 p.f.u.) from viral stocks (1 × 10 9 p.f.u./ml) of the TH:bFGF vector or of the THZ control vector. CNS distribution and transgene production were studied in 16 'naive' C57BL/6 mice which were killed 2 days, 1 week and 2 weeks after i.c. TH:bFGF vector injection. Naive C57BL/6 mice injected with the THZ vector and killed 1 week later were used as controls. EAE was induced in 12 mice. Twenty days p.i., mice with ongoing EAE were i.c. injected with the TH:bFGF or the THZ vector. All EAE mice were killed 60 days p.i.
EAE induction
Chronic-relapsing EAE was induced by subcutaneous immunization in both flanks of each mouse with 200 l of 200 g of myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 (Chiron, CA, USA) in complete Freund's adjuvant containing 4 mg/ml of Mycobacterium tuberculosis (strain H37Ra; Difco, Detroit, MI, USA). 29 Mice were i.p. injected with 500 ng of pertussis toxin (Sigma, St Louis, MO, USA) the day of immunization and 2 days later. Body weight and clinical score (0 = healthy; 1 = flaccid tail; 2 = ataxia and/or paresis of hindlimbs; 3 = paralysis of hindlimbs and/or paresis of forelimbs; 4 = tetraparalysis; 5 = moribund or death) were recorded daily.
FGF-II measurement
FGF-II was measured in CSF samples from 'naive' C57BL/6 mice i.c. injected with the TH:bFGF vector using a commercially available sandwich ELISA (R&D Systems, Minneapolis, MN, USA).
Neuropathology
At time of death, mice were transcardially perfused with 4% paraformaldehyde. Brains and spinal cords were removed, frozen and cut at 10 m. The following antibodies were used: mouse mAb anti-human FGF-II (Transduction Laboratories, Lexington, KY, USA); rabbit anti-HSV-1 polyclonal antibody (Accurate, New York, NY, USA); rabbit anti-human PDGFR␣ antibody crossreacting with mouse PDGFR␣ and recognizing oligodendrocyte precursors (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); peroxidase-labelled BS-I isolectin B4 staining macrophages (Sigma); rat anti-human CD3 antibody (pan-T cell marker cross-reacting with mouse CD3; Serotec Ltd, Oxford, UK). Appropriate biotin-labeled secondary antibodies (Amersham, Buckinghamshire, UK) were used followed by amplification with avidin-biotin complex (Vector, Burlingame, CA, USA). Perivascular inflammatory infiltrates were evaluated by hematoxylin and eosin (H&E), demyelinating areas by Luxol fast blue and axonal damage by Bielshowsky staining. A digoxigenin-labeled riboprobe specific for PLP mRNA was used to reveal myelin-forming oligodendrocytes, as previously described. 30 Neuropathological findings were quantified on an average of 20 spinal cord cross-sections per mouse which were taken at regular intervals throughout the whole spinal cord starting from the cervical region, as we have previously shown. 6 ,7 Perivascular infiltrates, macrophages, and T cells were expressed as number per mm 2 , while demyelination and axonal loss were expressed as percentage per mm 2 . PLP-and PDGFR␣-positive cells were counted on an average of 30-35 demyelinated areas, from both TH:bFGF-treated and THZ-treated control mice, and expressed as number of cells per mm 2 of demyelination.
